Insulin and the Receptor Network That Gates Glucose and Growth

Insulin is a peptide hormone made by the pancreatic beta cells as a single-chain precursor, preproinsulin, which is trimmed to proinsulin and stored in secretory granules. Just before release, proinsulin is cleaved by prohormone convertases into the mature two-chain insulin molecule (A and B chains linked by disulfide bonds) and a connecting peptide, C-peptide, which is co-secreted in roughly equimolar amounts. C-peptide is not inert: it has its own reported vasoprotective and tissue-signaling actions, and because it is cleared differently from insulin, measuring both gives a fuller picture of beta-cell output than insulin alone. The tight coupling of synthesis, storage, and stimulus-coupled cleavage is what allows insulin to be released precisely in response to rising blood glucose.

Browse More Insulin Products

The insulin receptor and the IGF receptor family

The insulin receptor (INSR) is a receptor tyrosine kinase built as a preformed alpha2-beta2 heterotetramer. Alternative splicing of exon 11 generates two isoforms: IR-A (lacking exon 11), which binds insulin and IGF-2 with high affinity and is the predominant form in fetuses, brain, and many tumors; and IR-B (including exon 11), the classic metabolic receptor of liver, muscle, and adipose tissue. INSR belongs to a small family with the IGF-1 receptor (which binds IGF-1 and IGF-2) and the more enigmatic insulin-receptor-related receptor. These receptors can also form hybrid dimers, so the "insulin receptor" in a given tissue is often a mixture whose composition shifts with development and disease. This receptor heterogeneity is central to why insulin signaling produces both metabolic and mitogenic outcomes, and why the axis is relevant to oncology as well as endocrinology.

Figure 1. Insulin-stimulated GLUT4 translocation via the PI3K/Akt signalling cascade. (Source: Bauer I, et al. 2024)

Interacting partners of the insulin axis

Insulin's actions are shaped by a set of ligands, receptors, transporters, and companion hormones that together define the metabolic network. The key molecules and their relationships are summarized below.

This ensemble view matters because disease and therapy rarely touch one limb in isolation. A defect in IRS/PI3K signaling, a shift toward the IR-A isoform, or an excess of counter-regulatory drive each reshapes the whole axis, which is why single-hormone measurements often fail to capture the underlying physiology.

The signaling cascade and glucose disposal

Insulin binding induces receptor autophosphorylation and recruitment of insulin-receptor substrates (IRS proteins), which in turn activate phosphatidylinositol 3-kinase (PI3K) and protein kinase B (AKT). AKT is the master switch for metabolic action: it drives translocation of the GLUT4 glucose transporter to the cell surface in muscle and fat (the step that actually clears glucose from blood), stimulates glycogen and lipid synthesis, and inhibits glucose production in the liver. A parallel branch through Grb2/SOS/Ras engages the MAPK pathway, contributing to growth and gene expression. The precision of this cascade — and its tight negative regulation by phosphatases and feedback loops — is what keeps glucose homeostasis in check, and the same machinery is co-opted when cells prioritize proliferation over metabolism.

Counter-regulatory and companion hormones

Insulin acts within a hormonal ensemble. Its counter-regulatory partner glucagon, released by pancreatic alpha cells during fasting, raises blood glucose by stimulating hepatic glucose output — the opposite pole to insulin's action. Amylin is co-secreted with insulin from beta cells and slows gastric emptying and suppresses glucagon, modulating the post-meal glucose rise. The incretin hormones GLP-1 and GIP, released from the gut after eating, amplify glucose-dependent insulin secretion and are themselves the basis for a major class of diabetes therapies. IGF-1 and IGF-2, read mainly through the IGF-1 receptor, overlap with insulin signaling in growth and survival. Understanding insulin therefore means understanding this whole cast, because metabolic disease is usually a systems problem rather than a single-hormone failure.

Figure 2. PI3K/AKT pathway in normal state and insulin resistance. (Source: Huang X, et al. 2018)

Insulin resistance and receptor isoform switching

A diminished cellular response to insulin — insulin resistance — forces the beta cell to secrete more (hyperinsulinemia) and, when compensation fails, leads to elevated glucose. It sits upstream of type 2 diabetes and intertwines with obesity, fatty liver, cardiovascular risk, and low-grade inflammation. At the molecular level, resistance reflects impaired IRS/PI3K/AKT signaling and defective GLUT4 trafficking. A separate research thread concerns INSR isoform switching: many cancers re-express the fetal IR-A isoform, which can sustain mitogenic signaling and even blunt the effect of therapies aimed at related receptors — a reason the insulin/IGF axis is studied in oncology as well as metabolism. Distinguishing the metabolic from the mitogenic face of the receptor is an active area of both basic and translational investigation.

How the insulin axis is measured

Measurement spans hormones, receptors, and downstream activation. Insulin and C-peptide are quantified by sandwich ELISA in serum or plasma, the latter useful for estimating endogenous beta-cell secretion. IGF-1 is likewise measured immunologically. Receptor presence and activation are read by Western blot or flow cytometry for the receptor and by phospho-specific ELISA/arrays for IRS and AKT phosphorylation. Glucose-handling is assessed functionally by tolerance tests and by GLUT4-translocation assays in cells. Because insulin resistance is a tissue-level phenomenon, no single blood value captures it; the interpretive power comes from combining hormone levels with a functional or phosphorylation readout.

For research and diagnostic teams, quantifying the axis means more than a single hormone. Our catalog supports this with insulin and C-peptide ELISA kits, insulin-receptor and IGF-1-receptor reagent sets, phospho-AKT/IRS pathway panels, and custom development for secretion and receptor-activation assays, enabling the network to be read as a whole rather than one molecule at a time.